A Multifunctional Hybrid Nanocarrier for Non-Invasive SiRNA Delivery to the Retina

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Feb 25

PMID 36839933

Authors

Shogo Nishida

Yuuki Takashima

Ryotaro Udagawa

Hisako Ibaraki

Yasuo Seta

Hiroshi Ishihara

Affiliations

Soon will be listed here.

Abstract

Drug therapy for retinal diseases (e.g., age-related macular degeneration, the leading cause of blindness) is generally performed by invasive intravitreal injection because of poor drug delivery caused by the blood-retinal barrier (BRB). This study aimed to develop a nanocarrier for the non-invasive delivery of small interfering RNA (siRNA) to the posterior segment of the eye (i.e., the retina) by eyedrops. To this end, we prepared a hybrid nanocarrier based on a multifunctional peptide and liposomes, and the composition was optimized. A cytoplasm-responsive stearylated peptide (STR-CH2R4H2C) was used as the multifunctional peptide because of its superior ability to enhance the complexation, cell permeation, and intracellular dynamics of siRNA. By adding STR-CH2R4H2C to the surface of liposomes, intracellular uptake increased regardless of the liposome surface charge. The STR-CH2R4H2C-modified cationic nanocarrier demonstrated significant siRNA transfection efficiency with no cytotoxicity, enhanced siRNA release from endosomes, and effectively suppressed vascular endothelial growth factor expression in rat retinal pigment epithelium cells. The 2.0 mol% STR-CH2R4H2C-modified cationic nanocarrier enhanced intraocular migration into the retina after instillation into rat eyes.

Citing Articles

Frontier applications of retinal nanomedicine: progress, challenges and perspectives.

Tang Z, Ye F, Ni N, Fan X, Lu L, Gu P J Nanobiotechnology. 2025; 23(1):143.

PMID: 40001147 PMC: 11863789. DOI: 10.1186/s12951-025-03095-6.

Co-delivery of antioxidants and siRNA-VEGF: promising treatment for age-related macular degeneration.

Dias M, Cruz-Cazarim E, Pittella F, Baiao A, Pacheco A, Sarmento B Drug Deliv Transl Res. 2025; .

PMID: 39751765 DOI: 10.1007/s13346-024-01772-x.

Polycondensed Peptide-Based Polymers for Targeted Delivery of Anti-Angiogenic siRNA to Treat Endometriosis.

Egorova A, Maretina M, Krylova I, Kiselev A Int J Mol Sci. 2024; 25(1).

PMID: 38203184 PMC: 10778610. DOI: 10.3390/ijms25010013.

Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases.

Mahaling B, Low S, Ch S, Addi U, Ahmad B, Connor T Pharmaceutics. 2023; 15(7).

PMID: 37514191 PMC: 10383092. DOI: 10.3390/pharmaceutics15072005.

References

Mulfaul K, Giacalone J, Voigt A, Riker M, Ochoa D, Han I . Stepwise differentiation and functional characterization of human induced pluripotent stem cell-derived choroidal endothelial cells. Stem Cell Res Ther. 2020; 11(1):409. PMC: 7510078. DOI: 10.1186/s13287-020-01903-4. View

Gorantla S, Rapalli V, Waghule T, Singh P, Dubey S, Saha R . Nanocarriers for ocular drug delivery: current status and translational opportunity. RSC Adv. 2022; 10(46):27835-27855. PMC: 9055630. DOI: 10.1039/d0ra04971a. View

Kobayashi S, Nakase I, Kawabata N, Yu H, Pujals S, Imanishi M . Cytosolic targeting of macromolecules using a pH-dependent fusogenic peptide in combination with cationic liposomes. Bioconjug Chem. 2009; 20(5):953-9. DOI: 10.1021/bc800530v. View

Fisher 3rd R, West P, Mattern-Schain S, Best M, Kirkpatrick S, Dieter 3rd R . Advances in the Formulation and Assembly of Non-Cationic Lipid Nanoparticles for the Medical Application of Gene Therapeutics. Nanomaterials (Basel). 2021; 11(3). PMC: 8004789. DOI: 10.3390/nano11030825. View

Collins E, Birchall J, Williams J, Gumbleton M . Nuclear localisation and pDNA condensation in non-viral gene delivery. J Gene Med. 2007; 9(4):265-74. DOI: 10.1002/jgm.1015. View

Lee D, Park J, Kwon S, Park J, Kim Y, Khang D . Apoptotic lysosomal proton sponge effect in tumor tissue by cationic gold nanorods. Nanoscale. 2019; 11(42):19980-19993. DOI: 10.1039/c9nr04323c. View

Lakkaraju A, Umapathy A, Tan L, Daniele L, Philp N, Boesze-Battaglia K . The cell biology of the retinal pigment epithelium. Prog Retin Eye Res. 2020; :100846. PMC: 8941496. DOI: 10.1016/j.preteyeres.2020.100846. View

Sreekumar P, Kannan R, de Silva A, Burton R, Ryan S, Hinton D . Thiol regulation of vascular endothelial growth factor-A and its receptors in human retinal pigment epithelial cells. Biochem Biophys Res Commun. 2006; 346(4):1200-6. DOI: 10.1016/j.bbrc.2006.06.021. View

Varela-Fernandez R, Diaz-Tome V, Luaces-Rodriguez A, Conde-Penedo A, Garcia-Otero X, Luzardo-Alvarez A . Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations. Pharmaceutics. 2020; 12(3). PMC: 7151081. DOI: 10.3390/pharmaceutics12030269. View

10.

Kolasinac R, Bier D, Schmitt L, Yabluchanskiy A, Neumaier B, Merkel R . Delivery of the Radionuclide I Using Cationic Fusogenic Liposomes as Nanocarriers. Int J Mol Sci. 2021; 22(1). PMC: 7796481. DOI: 10.3390/ijms22010457. View

11.

Suda K, Murakami T, Gotoh N, Fukuda R, Hashida Y, Hashida M . High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. J Control Release. 2017; 266:301-309. DOI: 10.1016/j.jconrel.2017.09.036. View

12.

Tai W, Gao X . Functional peptides for siRNA delivery. Adv Drug Deliv Rev. 2016; 110-111:157-168. PMC: 5305781. DOI: 10.1016/j.addr.2016.08.004. View

13.

Potocky T, Silvius J, Menon A, Gellman S . HeLa cell entry by guanidinium-rich beta-peptides: importance of specific cation-cell surface interactions. Chembiochem. 2007; 8(8):917-26. DOI: 10.1002/cbic.200600563. View

14.

Rothbard J, Jessop T, Lewis R, Murray B, Wender P . Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc. 2004; 126(31):9506-7. DOI: 10.1021/ja0482536. View

15.

de Vries V, Bassil F, Ramdas W . The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep. 2020; 10(1):13248. PMC: 7411061. DOI: 10.1038/s41598-020-70269-7. View

16.

Martins I, Redgrave T . Obesity and post-prandial lipid metabolism. Feast or famine?. J Nutr Biochem. 2004; 15(3):130-41. DOI: 10.1016/j.jnutbio.2003.10.006. View

17.

Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel U . Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. 2007; 21(11):2664-71. DOI: 10.1096/fj.06-6502com. View

18.

Rudraraju M, Narayanan S, Somanath P . Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy. Pharmacol Res. 2020; 161:105115. PMC: 7755666. DOI: 10.1016/j.phrs.2020.105115. View

19.

Ibaraki H, Kanazawa T, Takashima Y, Okada H, Seta Y . Transdermal anti-nuclear kappaB siRNA therapy for atopic dermatitis using a combination of two kinds of functional oligopeptide. Int J Pharm. 2018; 542(1-2):213-220. DOI: 10.1016/j.ijpharm.2018.03.026. View

20.

Tanaka K, Kanazawa T, Ogawa T, Takashima Y, Fukuda T, Okada H . Disulfide crosslinked stearoyl carrier peptides containing arginine and histidine enhance siRNA uptake and gene silencing. Int J Pharm. 2010; 398(1-2):219-24. DOI: 10.1016/j.ijpharm.2010.07.038. View